WeVote
Log In

Bill

Bill

SB 103

AN ACT relating to prescription drugs.

2026 Regular Session Introduced by Craig Richardson and 1 co-sponsor

Prohibits deceptive practices and enhances access and affordability of prescription drugs in Kentucky through pricing transparency and patient protections.

to Committee on Committees (S)
#actuarialanalysis #drugsandmedicines #education #higher #effectivedates #delayed #healthbenefitplanmandate #insurance #health #localmandate #pharmacists #stateemployeehealthplanmandate #stateemployees
0
WeVote Research Nonpartisan
Bill Summary · SB 103

Overview

SB 103 (2026 Regular Session, Kentucky) is an act relating to prescription drugs. Introduced in the Kentucky Senate on January 16, 2026, and referred to the Committee on Committees, the bill appears to address policy aspects of prescription drug regulation, affordability, safety, or access. The available information does not include the bill’s full text, amendments, or fiscal impact, so this summary focuses on the bill’s stated purpose and the typical scope of similar prescription drug legislation.

Purpose and Intent

  • Establishes or updates state-level policy regarding prescription drugs.
  • Aims to address concerns such as access to medications, affordability, pharmacy operations, or patient protections, consistent with Kentucky’s approach to drug regulation.
  • May seek to respond to public health needs, cost containment, or transparency in drug pricing and dispensing.

Key Provisions (Expected Content)

Note: Specific language is not provided in the available record. Based on typical components of prescription-drug-related bills, potential areas the bill could cover include:

  • Access and affordability

    • Provisions to cap or regulate out-of-pocket costs for commonly used medications.
    • Encouragement or requirements for generic substitution or use of therapeutically equivalent alternatives.

  • Pharmacy practice and dispensing

    • Standards for pharmacist dispensing, safety protocols, or patient counseling requirements.
    • Measures to combat drug shortages or ensure timely availability of critical medicines.

-Registration, reporting, and transparency
- Reporting requirements for drug pricing, rebates, or preferred-dr product lists.
- Transparency measures for patient protections or insurer-physician/pharmacist communications.

  • Generic and biosimilar use

    • Policies to promote the use of generics or biosimilars to reduce costs, including substitution rules or physician notification.

  • Consumer protections

    • Provisions to safeguard patients from deceptive practices, ensure informed consent, or protect vulnerable populations.

  • Public health and safety

    • Provisions related to controlled substances, opioid risk mitigation, or medication safety programs.

Who Would Be Affected

  • Patients and consumers who purchase or receive prescription medications in Kentucky.
  • Pharmacists, pharmacies, and pharmaceutical distributors operating in the state.
  • Health insurers, pharmacy benefit managers (PBMs), and healthcare providers involved in prescribing or dispensing drugs.
  • State and local public health entities implementing related programs.

Procedural and Timeline Aspects

  • Introduction: January 16, 2026, in the Kentucky Senate.
  • Committee action: Referred to the Committee on Committees (S) on the same day, indicating initial procedural steps and potential for further committee hearings, amendments, and a vote.
  • Next steps (typical): If advanced, the bill would proceed to additional committees (e.g., Health and Welfare, Judiciary, or Appropriations), potential floor debates in the Senate, and then, if passed, move to the House for consideration. The timeline for final passage would depend on legislative calendars and any negotiations or amendments.

Potential Impacts and Considerations

  • If aimed at affordability, the bill could influence patient costs, formulary design, and price transparency.
  • If focused on safety or access, it may enhance pharmacist authority, patient counseling, or reporting requirements.
  • Fiscal implications would depend on funded programs, state-level incentives, or regulatory changes; these would be clarified in the fiscal note accompanying the bill.

Notes

  • The precise text, specific provisions, and fiscal impact are not included in the provided record. For a complete understanding, the full bill draft, committee reports, and fiscal analyses should be reviewed once publicly available.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.